For the First Time, There’s a Pill for Postpartum Depression,
August 22, 2023

Earlier this month, the Food and Drug Administration approved zuranalone, the first pill for the treatment of post-partum depression (PPD). Click here to read the recent news coverage.

Olympic Gold Medalist Aly Raisman & Philanthropists Jamee and Peter Gregory Honored at 16th Annual HOPE Luncheon Seminar,
November 15, 2022

Our warmest thanks to the 300 supporters who came out for our Sixteenth Annual HOPE Luncheon Seminar on Wednesday, November 9. The event raised over $500,000 for HDRF’s research and received excellent coverage, including People and Good Day New York. The Luncheon had a powerful discussion on one of the most important crises of our time: “Teens and Depression: Addressing the Youth Mental Health Crisis.”

New Hope for PTSD Treatment,
May 16, 2019

Newly Identified Neural Circuit May Be Target for Future PTSD Treatments

A research team funded by the Hope for Depression Research Foundation (HDRF) has identified a specific circuit of young adult-born neurons in the brain that plays a key role in the recognition of a safe versus hazardous situations.

Their findings, recently published in Science, could pave the way for more targeted treatments for conditions such as PTSD that are associated with hypervigilance and recurrent distressing memories.

FDA Approves New Drug for Postpartum Depression,
March 22, 2019

One in nine women in the United States experience symptoms of postpartum depression, a terrifying illness that is often difficult to treat.

That’s why we’re excited by news that the FDA has approved Brexanolone, a drug over 40 years in the making that is the first ever to specifically target the condition. The approval of Brexanolone is a cause for celebration for the entire field of neuroscience.

Click here to read the full article…

Novel Depression Treatment in the News,
February 15, 2019

A new antidepressant is expected to soon be approved by the Food and Drug Administration.

The New York Times reported yesterday that an advisory panel at the agency has voted in favor of recommending approval of the new drug, the nasal spray Esketamine, to treat severely depressed patients.